Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

Brandee McKoon tried the traditional diets to lose weight but didn’t have much luck. The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

The Kokomo woman was pre-diabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines ... is an expanded indication the drug was granted from the Food and Drug Administration (FDA) back in March 2023.

More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...

Novo is under pressure to boost its development credentials in its rivalry with Zepbound-maker Eli Lilly after a late-stage trial read-out on another next-generation obesity drug known as ...

This hormone slows the rate of how the stomach is emptied and regulates blood sugar. Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound ... from the Food and Drug ...